logo BDSP

Base documentaire

  1. Cost-effectiveness of detecting and treating diabetic retinopathy.

    Article, Communication - En anglais

    Regenstrief conference. Washington DC USA, 1994/12/11.


    To determine, from the health insurer's perspective, the cost of preventing vision loss in patients with diabetes mellitus through ophthalmologic screening and treatment and to calculate the cost-effectiveness of these interventions as compared with that of other medical interventions.


    Computer modeling, incorporating data from population-based epidemiologic studies and multicenter clinical trials.

    Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings.


    Screening and treatment of eye disease in patients with diabetes mellitus costs $3190 per quality-adjusted life-year (QALY) saved.

    This average cost is a weighted average (based on prevalence of disease) of the cost-effectiveness of detecting and treating diabetic eye disease in those with insulin-dependent diabetes mellitus ($1996 per QALY), those with non-insulin-dependent diabetes mellitus (NIDDM) who use insulin for glycemic control ($2933 per QALY), and those with NIDDM who do not use insulin for glycemic control ($3530 per QALY).


    Our analysis indicates that prevention programs aimed at improving eye care for diabetic persons not only result in substantial federal budgetary savings but are highly cost-effective health investments for society.

    Ophthalmologic screening for diabetic persons is more cost-effective than many routinely provided health interventions.

    Because diabetic eye disease is the leading...

    Mots-clés Pascal : Rétinopathie, Diabète, Prévention, Dépistage, Coût, Economie santé, Programme sanitaire, Etats Unis, Amérique du Nord, Amérique, Homme, Oeil pathologie, Endocrinopathie, Santé publique

    Mots-clés Pascal anglais : Retinopathy, Diabetes mellitus, Prevention, Medical screening, Costs, Health economy, Sanitary program, United States, North America, America, Human, Eye disease, Endocrinopathy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0164915

    Code Inist : 002B21E01C. Création : 199608.